Compass Therapeutics' 2025 net loss widens as R&D costs jump

Compass Therapeutics

05/03/2026 12:37

Overview

Oncology-focused biopharma's net loss widened to $66.5 mln in 2025

Company's R&D expenses rose 32% due to increased manufacturing costs

Cash and marketable securities at year-end 2025 were $209 mln, funding operations into 2028

Outlook

Company expects tovecimig PFS/OS data in April 2026

Compass plans Phase 2 study of tovecimig in mid-2026

CTX-10726 Phase 1 enrollment starts Q1 2026, data expected in H2

Result Drivers

R&D EXPENSES - Increased R&D expenses were primarily due to higher manufacturing costs for tovecimig and CTX-10726

CLINICAL PROGRESS - Tovecimig met primary endpoint in Phase 2/3 study, with key secondary endpoint data expected soon

CASH POSITION - Co strengthened cash position with $209 mln at year-end, providing runway into 2028

Company press release: ID:nGNX61bRHv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$15.72 mln
Q4 Basic EPS
-$0.09
Q4 Income From Operations
-$17.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $12.00, about 110.9% above its March 4 closing price of $5.69

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)